Astellas/Pfizer Settle Dispute Over Lipitor Rights In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms also gain Japanese marketing approval for celecoxib for treatment of inflammation and pain associated with rheumatoid arthritis and osteoarthritis.